Plain-English translation of NCT04657068 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called , which is designed to work against certain cancers that have problems repairing their DNA. The medication is being tested both on its own and combined with standard chemotherapy drugs to see if it can help people with advanced or metastatic cancers, including ovarian, colorectal, pancreatic, and other solid tumors. Researchers want to understand how safe and effective the treatment is.
Many cancers have defects in their DNA repair systems, which makes them vulnerable to drugs that target those defects. This trial exists to find out whether this medication can take advantage of those weaknesses to stop cancer growth, and whether combining it with existing chemotherapy drugs might work even better.
You likely qualify if…
You likely don't qualify if…
Depending on which part of the trial you join, you would take the new medication by mouth either every day or on an intermittent schedule in 21-day treatment cycles. Some participants receive the medication alone, while others receive it combined with chemotherapy drugs like or . You'll have regular clinic visits for blood tests, imaging scans to measure your tumor, and check-ins to monitor how you're tolerating the treatment. The trial involves multiple study centers, and you'll need to commit to following study procedures and attending scheduled visits for as long as you remain on the treatment.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States